Abstract | BACKGROUND: METHODS: RESULTS: Of 138 GalNAc-T3+ cases, 46 revealed significant co-expression with GalNAc-T6. N-acetylgalactosaminyltransferases-3+ expression showed a close relationship to poor clinical performance and large tumour size, or pathologically high Fuhrman's grading, and presence of vascular invasion and necrosis. The GalNAc-T3-positivity potentially suppressed adhesive effects with a significantly low β- catenin expression. Univariate and multivariate analyses showed the GalNAc-T3+ group, but not the GalNAc-T6+ group, to have significantly worse survival rates. CONCLUSION: N-acetylgalactosaminyltransferases-3 expression independently predicts high-grade tumour and poor prognosis in patients with RCC, and may offer a therapeutic target against RCC.
|
Authors | S Kitada, S Yamada, A Kuma, S Ouchi, T Tasaki, A Nabeshima, H Noguchi, K-Y Wang, S Shimajiri, R Nakano, H Izumi, K Kohno, T Matsumoto, Y Sasaguri |
Journal | British journal of cancer
(Br J Cancer)
Vol. 109
Issue 2
Pg. 472-81
(Jul 23 2013)
ISSN: 1532-1827 [Electronic] England |
PMID | 23799843
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- N-Acetylgalactosaminyltransferases
- polypeptide N-acetylgalactosaminyltransferase
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(genetics, metabolism)
- Carcinoma, Renal Cell
(enzymology, pathology)
- Cell Line, Tumor
- Cohort Studies
- Female
- Humans
- Kidney Neoplasms
(enzymology, pathology)
- Male
- Middle Aged
- N-Acetylgalactosaminyltransferases
(genetics, metabolism)
- Neoplasm Grading
- Prognosis
- Retrospective Studies
|